<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Most <z:hpo ids='HP_0004377'>hematological neoplasms</z:hpo> associated with 11q23 chromosomal rearrangement have been cases of <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although cases of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a minority, these syndromes should also be recognized as part of the spectrum of <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e> associated with 11q23 rearrangement </plain></SENT>
<SENT sid="2" pm="."><plain>In this series of 550 patients with such rearrangement there were 28 (5.1%) who presented with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A further five patients had a history of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> but had evolved to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> by the time cytogenetic analysis was first undertaken </plain></SENT>
<SENT sid="4" pm="."><plain>There were thus a total of 33 patients (6.0%) with an 11q23 abnormality whose initial presentation was as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Of these 33 patients, a quarter (seven patients) were cases of secondary (therapy-related) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Complex karyotypes and other poor prognosis chromosomal abnormalities such as -7 and 7q- were common and were not confined to secondary cases </plain></SENT>
<SENT sid="7" pm="."><plain>The likelihood of presentation as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> differed between different cytogenetic categories </plain></SENT>
<SENT sid="8" pm="."><plain>The 28 patients in whom cytogenetic analysis was performed at presentation as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> showed a wide age distribution, from 1 to 82 years; there were four children, two of 1 year of age </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> FAB types of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were represented </plain></SENT>
<SENT sid="10" pm="."><plain>Median survival was only 19.1 months </plain></SENT>
<SENT sid="11" pm="."><plain>Leukemic transformation occurred in five patients including one case of transformation to a biphenotypic M5a/T-lineage <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
</text></document>